IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4848
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$4M
James Bianco
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
Headcount
—
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$HURA TuHURA Biosciences, Inc./NV | 20 | 15 | 1 | 4 | - | - | -150.8% | -98.5% | - | - | - | - | 0.0% | 53.0x | $4M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
TuHURA Biosciences, Inc./NV (HURA) receives a "Avoid" rating with a composite score of 19.9/100. It ranks #4848 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
Pending Verification
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for HURA.
View All RatingsROE proxy -150.8% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 9yr history
Interest coverage -407.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate TuHURA Biosciences, Inc./NV (HURA) as Avoid with a composite score of 19.9/100 at a current price of $1.39. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
TuHURA Biosciences, Inc./NV holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 19.9/100 places it at rank #4848 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
TuHURA Biosciences, Inc./NV represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags TuHURA Biosciences, Inc./NV with an Avoid rating, assigning a composite score of 19.9/100 and 1 out of 5 stars. Ranked #4848 of 7,333 stocks, HURA falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
TuHURA Biosciences, Inc./NV registers a weak quality score of just 15/100, indicating significant profitability challenges. The company reports a return on equity of -150.8% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
HURA registers a value score of just 1/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.87x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
TuHURA Biosciences, Inc./NV's investment score of 21/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -98.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
TuHURA Biosciences, Inc./NV is experiencing notably weak momentum with a score of just 4/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.37 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
TuHURA Biosciences, Inc./NV registers a low stability score of 17/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.37 and a debt-to-equity ratio of 53.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
TuHURA Biosciences, Inc./NV's short interest score of 15/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.37), elevated leverage (D/E: 53.00x), micro-cap liquidity risk. At $4M (micro-cap), HURA carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
TuHURA Biosciences, Inc./NV is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4848 of 7,333 overall (34th percentile). Key comparisons include ROE of -150.8% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HURA currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (1) would have the largest impact on the composite score.
ROE 5981% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 26400% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
TuHURA Biosciences, Inc. (NASDAQ:HURA) has received a consensus "Buy" rating from six brokerages, with an average one-year target price of $10.33. The Phase 3 immuno-oncology company, developing IFx-2.0, recently reported an EPS of -$0.14, beating estimates. Institutional ownership is low at 0.62%, and the stock has been volatile, trading between $0.93 and $5.50 over the last 12 months.
TuHURA Biosciences provided a corporate update following a recent $15.6 million equity financing, outlining key program milestones for 2026. These include the expected completion of enrollment for its Phase 3 IFx-2.0 trial in Merkel Cell Carcinoma (MCC) by Q4 2026, initiation of a Phase 2 trial for its VISTA inhibiting antibody (TBS-2025) in AML, and presentation of preclinical data for its Delta Opioid Receptor (DOR) targeted Antibody Drug Conjugate (ADC) program. The financing aims to fund these multiple near-term milestones across its three development programs.
TuHURA Biosciences' shares plunged 36.9% after the company entered an agreement for a registered direct offering of approximately 9.5 million shares, Series A and Series B warrants, for gross proceeds of $15.6 million. The proceeds from this offering will be used for working capital and general purposes. All three analysts covering HURA stock rate it "buy," with a median price target of $9.13, despite the stock being down 51.6% YTD as of its last close.
Wall Street Zen upgraded TuHURA Biosciences (NASDAQ:HURA) from a "sell" to a "hold" rating, indicating a moderated outlook. Despite this, the analyst consensus remains a "Buy" with a $10.33 average price target, though recent adjustments include Maxim Group cutting its target from $15.00 to $8.00. TuHURA Biosciences reported quarterly EPS of ($0.14), beating estimates by $0.01, and institutional investors have recently adjusted their positions in the company.
TuHURA Biosciences, Inc. is expected to achieve profitability in 2027, according to American Biotech analysts, after posting a US$19m trailing-twelve-month loss. The company is projected to turn a profit of US$14m in 2027, driven by an estimated annual growth rate of 65%. Investors are advised to consider the company's negative equity and the lumpy cash flow typical of biotech firms.